Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is
an autoimmune demyelinating polyradiculoneuropathy characterized by chronically progressive weakness and impaired sensory function in the lower and upper extremities. 1 Symptoms, which are progressive over at least 8 weeks, may include weakness of the arms and legs (both proximal and distal), loss of vibration and joint position sense, poor balance, numbness, paresthesias, and loss of deep tendon reflexes (areflexia).
Cranial nerves (other than cranial nerve V or VII) and autonomic functions are generally preserved. 2 The phenotype of symmetrical proximal and distal motor and sensory symptoms and signs define typical CIDP. Atypical CIDP includes other clinical presentations, such as asymmetric, multifocal motor and sensory symptoms, distal sensory, or predominantly motor or sensory types. Moreover, up to 16% of patients with CIDP may demonstrate acute-onset CIDP, which is characterized by a rapidly progressive onset within 8 weeks. 3, 4 The exact mechanisms that underlie the development of CIDP have not been elucidated fully, although evidence suggests likely contributions by both cellular and humoral factors. It is twice as common in men, with increasing frequency after age 60, although it can occur at any age. 5 The incidence and prevalence of CIDP have been estimated at 1.6/100,000/year to 8.9/100,000, respectively. 6 There are many phenotypic variants of CIDP (Table 1) , which suggests that the disorder may not be a discrete entity, but a spectrum of conditions. 7 Elevated levels of cerebrospinal fluid (CSF) protein are present in the majority of patients although normal CSF results do not exclude the diagnosis of CIDP. 7, 8 Currently, there are no well-established biomarkers, although autoantibodies to contactin-1 and neurofascin-155 define CIDP subsets of patients with specific clinical features. 9 
Diagnosis
Early diagnosis is vital for this treatable condition in order to limit disability as a result of secondary axonal damage. Initial diagnostic criteria, including Electrodiagnostic testing is essential to make the diagnosis, EFNS/PNS electrodiagnostic criteria for definite or probable diagnosis of CIDP require the presence of demyelinating findings (DF) in at least 2 nerves; for possible CIDP, abnormality may need to be evident only in 1 nerve. 10 The DF can include any of those abnormal parameters: Prolongation of distal motor latency (>50%), slowing of conduction velocity (<30%), absence or prolongation of F response latencies, presence of partial conduction block (50% for definite, 30% for probable), and abnormal temporal dispersion (>30% prolongation of CMAP duration between distal and proximal CMAP).
Preliminary evidence suggests that more extensive testing such as 8 motor nerves 13 or 3-rather than 2-limb testing may increase the diagnostic sensitivity for definite CIDP, particularly in individuals with atypical (asymmetric and distal) phenotypes, which comprised 75.5% (40 of 53) of the study cohort. 14 With unilateral, forearm/foreleg, four-nerve studies the EFNS/PNS criteria has been reported to provide a sensitivity of 81.3% and specificity of 96.2%
for "definite/probable" CIDP. 15 Supportive criteria include an elevated CSF protein with leukocyte count <10/mm 3 per high powered field, magnetic resonance imaging (MRI) of the nerve roots, nerve biopsy, and treatment response to immunomodulatory therapy. For diagnosis, objective measures should be used to verify and apply the criterion of treatment response.
Electrodiagnostic studies including sensory and motor nerve conduction studies should be performed; studies may need to be performed bilaterally, or use proximal stimulation in motor nerves in order to document multifocal demyelination. In the Koski criteria, according to a classification rule, which was derived by a classification and regression tree analysis and applied to 150 patients, the diagnosis of CIDP required that a patient had a chronic nongenetic polyneuropathy, progressive for at least 8 weeks, without a serum paraprotein and either: 16 • recordable compound muscle action potentials in ≥75% of motor nerves tested and either an abnormal distal latency in >50% of nerves or abnormal motor conduction velocity in >50% of nerves or abnormal F wave latency in >50% of nerves;
• symmetrical onset of weakness, symmetrical weakness in all four limbs and proximal weakness in ≥one limb.
The Koski criteria have 50-83% sensitivity and 89-97% specificity for typical presentations of CIDP.
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Chronic inflammatory demyelinating polyradiculoneuropathy and diabetes mellitus 18 The presence of DM was assessed using the data reported in the clinical records of each patient (clinical history, fasting blood glucose, or reported use of anti-diabetes drugs). In total, 155 patients with CIDP were identified, 14 of whom were also affected by DM (type 1 or 2). An investigation of incidence and prevalence in Olmsted Country (1581 medical records) identified 23 patients with CIDP (19 definite and 4 probable). The incidence of CIDP was 1.6/100,000/year and the prevalence was 8.9/100,000 persons on January 1, 2000. Only one of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age-and sexmatched controls (12%) had DM. 6 The findings of these studies therefore do not support an increased incidence of DM in patients with CIDP. 6, 18 However, it is possible that some CIDP patients were not identified or that some CIDP cases with associated DM, or preclinical DM, were missed. CIDP may occur with equal frequency in patients with types 1 and 2 DM, 19 presenting a diagnostic challenge: both CIDP and diabetes may result in elevated CSF protein. 20 Pathologic evaluation clearly differentiates diabetic lumbosacral radiculoplexus neuropathy (DLRPN) from CIDP. These patients would not meet electrophysiologic or clinical criteria for CIDP. This study concluded that the painless motor neuropathy seen in diabetic patients represents painless DLRPN and not CIDP. 21 However, a consideration of concomitant CIDP in patients with DM is important since treatment of demyelinating neuropathy would limit disability. It is key to consider a diagnosis of CIDP when diabetic patients develop relatively symmetrical proximal weakness or rapid worsening of neuropathy despite good glycemic control.
In an observational, retrospective study of CIDP patients with (n=67) and 
Differential Diagnosis
Neurological examination investigating sensory, motor, and autonomic signs help to define the topography and nature of neuropathy. Principal laboratory studies to support of the diagnosis of CIDP are CSF examination, nerve conduction studies, and nerve biopsy. 23 If a paraprotein is detected on serum immunofixation or serum kappa lambda free light chain ratio, a lymphoproliferative disorder, such as osteosclerotic myeloma or lymphoma, should be considered. 23 There is no biomarker for CIDP and differential diagnosis can be challenging as hereditary, toxic, metabolic, and neoplastic neuropathies must be considered. In a retrospective study of 59 patients who had been referred with a diagnosis of CIDP, patients were classified into whether or not they had CIDP according to the EFNS/PNS criteria. 24 Nearly half (47%) of these patients failed to meet the minimal EFNS/ PNS diagnostic requirements. Another study of patients, diagnosed with CIDP and referred after not responding to initial trials of treatment, found that 54% of patients had an alternative diagnosis, the most common of which was amyotrophic lateral sclerosis. Forty-six percent of refractory patients had CIDP though, and the majority responded to escalating immunotherapy. 25 Common diagnostic errors included dependence on subjective treatment benefit, imprecise electrophysiological interpretation of demyelination, and placing too much importance on mild or moderate cytoalbuminologic dissociation. There is also a large group of patients with presumed CIDP, who do not fulfill any of the proposed electrodiagnostic criteria. 26 Examples of some confounding diagnoses include:
Guillain-Barré syndrome (GBS) is a monophasic disorder that includes a spectrum of acute autoimmune peripheral neuropathies. It is less common than CIDP and frequently preceded by a triggering event including viral and diarrheal illness. CIDP has a much slower onset than GBS and a more chronic course. The first symptoms in GBS are typically pain, numbness, paresthesia, or weakness in the limbs. 27, 28 Main features include rapidly progressive bilateral and relatively symmetric weakness of the limbs and reduced or absent tendon reflexes in the affected extremities. Respiratory muscles, cranial nerves, and autonomic nerves are often affected in GBS. 28 Patients with CIDP may show a GBS-like onset and a CIDP diagnosis should be considered when a patient thought to have GBS relapses or progresses beyond 8 weeks from onset or when deterioration occurs three times or more. 2 Neuropathy ultrasound may be a useful addition as a diagnostic tool. POEMS syndrome, the other manifestations are subtle, and the primary problem is the demyelinating neuropathy. 32 Correct diagnosis was only made after the patients failed to respond to the standard treatment.
POEMS syndrome is associated with plasma cell dyscrasia of an IgA or IgG lambda paraprotein and a spectrum of multisystem clinical features. 33 It presents with neuropathy typified by motor and sensory 36 Elevated levels of vascular endothelial growth factor may also be helpful in making a diagnosis of POEMS syndrome. A skeletal survey is recommended in patients with a demyelinating polyneuropathy and a lambda monoclonal protein to detect osteosclerotic lesions.
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Treatment Corticosteroids
The EFNS/PNS guidelines recommend that a trial of corticosteroids, IVIG, or plasmapheresis should be considered in all patients with significant disability.
12 Supporting evidence in an unblinded, randomized, controlled trial (n=28), showed that prednisone treatment led to a small but significant improvement over no treatment in scored neurological disability, some measures of computer-assisted sensory detection threshold, graded muscle strength, and some attributes of nerve conduction. 40, 41 Pulsed oral dexamethasone therapy showed equal efficacy to oral prednisolone in a 6-month randomized clinical trial. 42 Steroids are accepted as firstline therapy for those patients with sensory and motor dysfunction who can tolerate steroids but should not be used in patients who present with motor variant CIDP, in which corticosteroids are reported to cause worsening.
12,43,44 Pure motor CIDP can sometimes be confused with MMN, in which corticosteroid treatment can also result in clinical worsening.
The long-term use of corticosteroids is associated with numerous side effects, some serious. These include osteoporosis, skin fragility, weight gain, diabetes, worsening hypertension, hip fractures, cataracts, sleeplessness, and cushingoid appearance. 41 
Intravenous immunoglobulin
IVIG has been an accepted as first-line therapy for the treatment of CIDP over the last 20 years and is supported by Class I evidence.
12, 45 The largest trial reported of any CIDP treatment is the ICE trial, which is a randomized, double-blind, placebo-controlled, response-conditional crossover trial of 117 patients with CIDP ( Figure 1) . 46 The aim of the ICE trial was to establish whether immune globulin injection (human), 10%, caprylate/ chromatography purified (IVIG-C; GAMUNEX ® -C, Grifols Therapeutics Inc., Clayton, North Carolina, US) has short-and long-term benefit.
The trial utilized a baseline loading dose of 2 g/kg over 2-4 days and then a maintenance infusion of 1 g/kg over 1-2 days, every 3 weeks, for up to 24 weeks. Participants who completed the first period or crossover period and whose improved INCAT disability score was consistently ≥1 point greater than at baseline were eligible for inclusion in a 24-week, double-blind extension phase. Eligible participants were randomly re-assigned in a 1:1 ratio to receive 1 g/kg IVIG or placebo over 1-2 days, In clinical practice, patients may take longer than 6 weeks to respond.
The novel response-conditional, crossover study design of the ICE trial required that patients cross over to the alternative treatment if they failed to improve or at the first sign of deterioration or if they were unable to maintain improvement at any time after 6 weeks ( Figure 1) . 49 This design addressed concerns about lack of clinical equipoise, which were raised by the physicians interested in participating in the trial. 49 The magnitude of change in CIDP outcome measures required to correlate with a perception of a clinical improvement in the ICE trial has been described through minimum clinically important differences analysis. In the ICE study, IVIG also led to health-related quality of life improvements. 52 In the first period, compared with placebo, greater improvements were observed in both SF-36 physical and mental component score (difference: 
Plasma exchange
Plasma exchange (PLEX) has been established as first-line therapy for CIDP in short-term efficacy studies. PLEX should be considered for initial treatment if patients cannot tolerate corticosteroids or IVIG, or have continued to deteriorate following IVIG or corticosteroids. 12 The temporal effect is short term, and an indwelling apheresis catheter may be required. Two small double-blind, sham-controlled, randomized clinical trials totaling 47 participants showed that PLEX provides short-term benefit in around two-thirds of patients but that rapid deterioration often ensues when the PLEX is stopped. [54] [55] [56] The use of PLEX is associated with adverse events related to difficulty with venous access, use of citrate, and haemodynamic changes. 57 
Immunosuppressive agents
The EFNS/PNS guidelines conclude that more research is needed before evidence-based recommendation on immunosuppressive treatment can be made; however, these treatments, including IV pulse cyclophosphamide, 57, 58 may be considered when the response to corticosteroids, IVIG, or PLEX is inadequate. 12 Although there have been reports on their potential use by case report or open-label studies, randomized, controlled clinical trials to date have not established efficacy of such agents as primary or as add-on agents in the treatment of CIDP.
59,60
Risk of relapse
Electrodiagnostic studies have been carried out on participants in the ICE trial who responded to treatment in the first period and were subsequently re-randomized to placebo in the 24-week extension phase. These data indicated that an increase in the total number of DF, specifically conduction block, may signal an increased risk of relapse after discontinuation of therapy whereas the absence of new demyelination may suggest a decreased risk of subsequent relapse. 60 
Autoantigens in chronic inflammatory demyelinating polyradiculoneuropathy
Recently, autoantibodies against membrane proteins of the peripheral nerve axons or the myelin sheath have been reported in CIDP. For example, a major component of myelin, protein zero (P0) is a target antigen in some patients with CIDP. 61 Antibodies to neurofascin and contactin-1, which are concentrated near the nodes of Ranvier, are found in a small population of patients with CIDP. 62 In a few patients, IgG4 antibodies to the paranodal proteins contactin and NF155 have been associated with severe, intravenous immunoglobulin (IVIG)-resistant CIDP. 63, 64 A subset of IVIG-resistant patients with contactin or NF-155 antibodies have responded to rituximab. 65, 66 Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with IVIG products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, DM, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable. Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease In clinical studies, the most common adverse reactions with GAMUNEX-C were headache, fever, chills, hypertension, rash, nausea, and asthenia (in CIDP); headache, cough, injection-site reaction, nausea, pharyngitis, and urticaria with intravenous use (in PIDD) and infusion-site reactions, headache, influenza, fatigue, arthralgia, and pyrexia with subcutaneous use (in PIDD); and headache, vomiting, fever, nausea, back pain, and rash (in ITP).
The most serious adverse reactions in clinical studies were pulmonary embolism (PE) in 1 subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in 1 subject (in PIDD), and myocarditis in 1 subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).
Please see the brief summary of full Prescribing Information for GAMUNEX-C in the Appendix. q
